Close Menu

NEW YORK – Despite the ongoing trade war between the US and China, the Chinese diagnostics space remains a robust opportunity, according to industry players and experts. 

But as the Chinese government pushes ahead with its ambitious plan to improve the healthcare of its 1.4 billion citizens, multinational diagnostic companies doing business in the country will need to adapt to a dynamic and evolving market.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.